| Date | Title | Description |
| 22.11.2022 | Modus Therapeutics publishes interim report for the third quarter 2022 | Modus Therapeutics publishes interim report for the third quarter 2022
Tue, Nov 22, 2022 08:00 CET Report this content
STOCKHOLM, SWEDEN - 22 November 2022: Modus Therapeutics Holding AB (” Modus Therapeutics”) hereby publishes an interim r... |
| 01.09.2022 | Modus Therapeutics announces first patient enrolled in the Phase I SEVUSMART clinical trial evaluating sevuparin in paediatric patients with severe malaria | Modus Therapeutics announces first patient enrolled in the Phase I SEVUSMART clinical trial evaluating sevuparin in paediatric patients with severe malaria
Thu, Sep 01, 2022 22:25 CET Report this content
STOCKHOLM, SWEDEN – 1 September 2022... |
| 23.08.2022 | Modus Therapeutics publishes interim report for the second quarter 2022 | Modus Therapeutics publishes interim report for the second quarter 2022
Tue, Aug 23, 2022 08:00 CET Report this content
STOCKHOLM, SWEDEN - 23 August 2022: Modus Therapeutics Holding AB (” Modus Therapeutics”) hereby publishes an interim re... |
| 10.06.2022 | Modus Therapeutics presents at småbolagsdagarna | Modus Therapeutics presents at småbolagsdagarna
Fri, Jun 10, 2022 15:00 CET Report this content
Stockholm, Friday, June 10, 2022. Modus Therapeutics Holding AB ("Modus") announces that the company will participate at aktiespararna... |
| 25.05.2022 | Modus Therapeutics Updates on Sevuparin Phase 1b Clinical Trial Timelines | Modus Therapeutics Updates on Sevuparin Phase 1b Clinical Trial Timelines
Wed, May 25, 2022 17:57 CET Report this content
STOCKHOLM, SWEDEN – 25 May 2022: Modus Therapeutics Holding AB, a biopharma company focused on the clinical developmen... |
| 16.05.2022 | Modus Therapeutics publishes interim report for the first quarter 2022 | Modus Therapeutics publishes interim report for the first quarter 2022
Mon, May 16, 2022 08:00 CET Report this content
STOCKHOLM, SWEDEN - 16 May 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report ... |
| 12.05.2022 | Modus Therapeutics secures access to bridge financing from Karolinska Development | Modus Therapeutics secures access to bridge financing from Karolinska Development
Thu, May 12, 2022 16:22 CET Report this content
STOCKHOLM, SWEDEN - 12 May 2022: Modus Therapeutics Holding AB (“Modus”) announces that it has secured access ... |
| 11.05.2022 | Annual General Meeting in Modus Therapeutics Holding AB (publ) | Annual General Meeting in Modus Therapeutics Holding AB (publ)
Wed, May 11, 2022 14:45 CET Report this content
Today, the annual general meeting of 2022 was held in Modus Therapeutics Holding AB (publ). Below is a summary of the resolutions... |
| 22.04.2022 | New publication date for Modus Therapeutics’ interim report for the first quarter | New publication date for Modus Therapeutics’ interim report for the first quarter
Fri, Apr 22, 2022 17:00 CET Report this content
Stockholm, Sweden–April 22th 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby announces that ... |
| 19.04.2022 | Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2021 | Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2021
Tue, Apr 19, 2022 08:00 CET Report this content
Stockholm, Sweden–April 19th 2022: Modus Therapeutics Holding AB (publ) (”Modus Therapeutics”) announce... |
| 12.04.2022 | Notice to Annual General Meeting in Modus Therapeutics Holding | Notice to Annual General Meeting in Modus Therapeutics Holding
Tue, Apr 12, 2022 09:00 CET Report this content
The shareholders of Modus Therapeutics Holding AB (publ) are invited to the annual general meeting on Wednesday, 11 May 2022, at ... |
| 24.02.2022 | Modus Therapeutics to present at the Erik Penser Bank Health Care Day | Modus Therapeutics to present at the Erik Penser Bank Health Care Day
Thu, Feb 24, 2022 10:30 CET Report this content
Stockholm, Thursday, February 24, 2022. Modus Therapeutics Holding AB ("Modus") announces that the company will ... |
| 22.02.2022 | Modus Therapeutics publishes year-end report for 2021 | Modus Therapeutics publishes year-end report for 2021
Tue, Feb 22, 2022 08:00 CET Report this content
STOCKHOLM, SWEDEN - 22 February 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes a year-end report for 2021. Th... |
| 14.01.2022 | Modus Therapeutics sums up the significant progress on key milestones during 2021, including IPO on First North Stockholm | Modus Therapeutics sums up the significant progress on key milestones during 2021, including IPO on First North Stockholm Fri, Jan 14, 2022 08:00 CET
Stockholm, Sweden – January 14th 2022: Modus Therapeutics AB, a company developing innovat... |
| 14.12.2021 | Modus Therapeutics participates in Aktier Live Sessions | Modus Therapeutics participates in Aktier Live Sessions Tue, Dec 14, 2021 08:30 CET
Stockholm, Tuesday, December 14, 2021. Modus Therapeutics Holding AB ("Modus") announces that the company participates in today’s Aktier Live Sess... |
| 02.12.2021 | Modus Therapeutics comments on the start of the first clinical study in the planned sepsis program | Modus Therapeutics comments on the start of the first clinical study in the planned sepsis program Thu, Dec 02, 2021 11:00 CET
Stockholm, Thursday, December 2, 2021. Modus Therapeutics Holding AB ("Modus") announces that the compa... |
| 01.12.2021 | First sevuparin dose administered in Modus Therapeutics’ Phase 1b LPS provocation study | First sevuparin dose administered in Modus Therapeutics’ Phase 1b LPS provocation study Wed, Dec 01, 2021 10:33 CET
STOCKHOLM, SWEDEN – December 1, 2021: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments fo... |
| 18.11.2021 | Modus Therapeutics publishes interim report for the third quarter 2021 | Modus Therapeutics publishes interim report for the third quarter 2021 Thu, Nov 18, 2021 08:00 CET
STOCKHOLM, SWEDEN - 18 November 2021: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the third q... |
| 09.11.2021 | Modus Therapeutics Receives Regulatory Approval to Start a Phase 1b Clinical LPS Challenge Study with Sevuparin in the Netherlands | Modus Therapeutics Receives Regulatory Approval to Start a Phase 1b Clinical LPS Challenge Study with Sevuparin in the Netherlands Tue, Nov 09, 2021 16:32 CET
STOCKHOLM, SWEDEN – 9 November 2021: Modus Therapeutics Holding AB (“Modus”), a c... |
| 27.10.2021 | Modus Therapeutics participates in Småbolagspodden | Modus Therapeutics participates in Småbolagspodden Wed, Oct 27, 2021 08:30 CET
Stockholm, Wednesday, October 27, 2021. Modus Therapeutics Holding AB ("Modus") announces that the company participates in the latest episode of Småbol... |
| 19.10.2021 | Modus Therapeutics participates in the Biostock Life Science Summit 2021 | Modus Therapeutics participates in the Biostock Life Science Summit 2021 Tue, Oct 19, 2021 08:30 CET
Stockholm, Tuesday 19 October 2021. Modus Therapeutics Holding AB ("Modus") announces today that the company's CEO John Öhd will ... |
| 12.10.2021 | Modus Therapeutics - Symbiosis Pharmaceutical Services Starts Producing Sevuparin for Modus’ Future Clinical Development in Sepsis/septic shock | Modus Therapeutics - Symbiosis Pharmaceutical Services Starts Producing Sevuparin for Modus’ Future Clinical Development in Sepsis/septic shock Tue, Oct 12, 2021 08:30 CET
STOCKHOLM, SWEDEN – 12 October 2021: Modus Therapeutics Holding AB (... |
| 23.09.2021 | Modus Therapeutics Appoints Key Scientific Advisors | Modus Therapeutics Appoints Key Scientific Advisors Thu, Sep 23, 2021 09:00 CET
STOCKHOLM, SWEDEN – 23 September 2021: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical ... |
| 17.09.2021 | Modus Therapeutics participates in FS markets Investment Meeting-Live on September 23rd | Modus Therapeutics participates in FS markets Investment Meeting-Live on September 23rd Fri, Sep 17, 2021 11:42 CET
On Thursday, 23 September 2021 at 5.30 pm, Modus Therapeutics AB (“Modus”) will participate in FS Markets Investerarmötet-Li... |
| 19.08.2021 | Modus Therapeutics publishes interim report for the second quarter 2021 | Modus Therapeutics publishes interim report for the second quarter 2021 Thu, Aug 19, 2021 08:00 CET
STOCKHOLM, SWEDEN - 19 august 2021: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the second q... |
| 15.07.2021 | Karolinska Development : portfolio company Modus Therapeutics raises SEK 33 million through an oversubscribed issue and now prepares for listing | STOCKHOLM, SWEDEN – July 15, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Modus Therapeutics has completed an oversubscribed issue of units (113% subscription rate), providing the compa... |
| 15.07.2021 | Modus Therapeutics issue of units prior to listing was oversubscribed | Modus Therapeutics issue of units prior to listing was oversubscribed Thu, Jul 15, 2021 15:26 CET
STOCKHOLM, SWEDEN – July 15, 2021: On July 13, 2021, the subscription period in Modus Therapeutics Holding AB ("Modus Therapeutics" ... |
| 16.07.2018 | Term Sheet — Monday, July 16 | BRAINSTORM TECH DAY 1
Good morning from Aspen!
Paid Content What you need to know about growing cyberattacks From ExtraHop
We’ll kick it off with a conversation between Fortune executive editor Adam Lashinsky and Uber CEO Dara Khosrowshahi.... |
| 13.07.2018 | Modus Therapeutics Completes a SEK140M Financing | Modus Therapeutics AB, a Stockholm, Sweden-based company developing innovative treatments in unmet medical need disease areas with a focus on sickle cell disease (SCD), raised SEK140m in financing.
The round was led by new investor HealthCa... |
| 13.07.2018 | Swedish developer Modus brings in $15M to fund sickle cell drug | Modus Therapeutics has raised over 140 million Swedish krona, or about $15.7 million, to advance clinical development of the company’s compound for sickle cell disease.
The series A financing round was led by European venture capital firm H... |
| 13.07.2018 | Swedish developer Modus brings in $15M to fund sickle cell drug | Modus Therapeutics has raised over 140 million Swedish krona, or about $15.7 million, to advance clinical development of the company’s compound for sickle cell disease.
Sponsored by Agilent Technologies
How would you like to win free bench ... |
| 23.02.2017 | Term Sheet — Thursday, February 23 | Cirque du LBO
Fortune’s latest feature story, published this morning by my colleague Michal Lev-Ram, is about what happens when private equity takes over the circus. Specifically, TPG Capital and Cirque du Soleil, which the firm acquired in... |
| 21.02.2017 | Modus Therapeutics Raises SEK 32M in Funding | Modus Therapeutics AB, a Stockholm, Sweden-based company focused on innovative treatments for patients with sickle cell disease, completed a financing round of SEK 32m.
Backers included existing investors KDev Investments, part of Karolinsk... |
| - | Modus Therapeutics completes enrollment of randomized, placebo-controlled Phase II clinical trial evaluating sevuparin for management of Acute Vaso-Occlusive Crisis in SCD patients | STOCKHOLM, SWEDEN – 07 January 2019: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announces that it has completed patient enrollment in... |
| - | Modus Therapeutics announces FDA Acceptance of Sevuparin IND for treatment of sickle cell disease | Modus Therapeutics AB, a company developing innovative treatments in disease areas with high unmet medical need with a focus on sickle cell disease (SCD), announces that the FDA has accepted its sevuparin IND for the treatment of SCD.
“The... |
| - | Modus Therapeutics strengthens Board with two key appointments | STOCKHOLM, SWEDEN – 29 January 2019: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announcesthe appointment of two new Board members.
S... |
| - | HealthCap makes 112th investment as Swedish company Modus Therapeutics completes SEK 140 million financing led by HealthCap | Funds to be used to continue the clinical development of sevuparin for sickle cell disease
STOCKHOLM, SWEDEN – 13 July 2018: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a ... |
| - | Modus announces First Cohort Dosed in U.S. Phase 1 Study of Subcutaneously Administered Sevuparin | STOCKHOLM, SWEDEN – 22 February 2019: Modus Therapeutics AB, a company developing innovative treatments for patients with high unmet medical needs and a focus on sickle cell disease (SCD), announces that the first cohort has been successful... |
| - | Modus Therapeutics | “Home - Modus Therapeutics” |
| - | Modus Therapeutics strengthens management team with appointment of Mats Blom, MBA as CFO | STOCKHOLM, SWEDEN – 11 March 2019: Modus Therapeutics AB, a company developing innovative treatments for patients with high unmet medical needs and a focus on sickle cell disease (SCD), announces the appointment of Mats Blom as Chief Financ... |
